News ESMO26: BMS dual-acting ADC beats chemo in breast cancer BMS and SystImmune's EGFRxHER3 bispecific ADC iza-bren has scored in another phase 3 trial, boosting its credentials as a future blockbuster.
News Mixed data from lung cancer trials on show at WCLC Highlights of the WCLC show include new data for AstraZeneca's Tagrisso, Summit's ivonescimab, MSD/Daiichi's I-DXd, and BMS/Systimmune's iza-bren.
News BMS bolts on SystImmune bispecific ADC in $8.4bn deal The litany of big-ticket deals involving antibody-drug conjugates shows no sign of ending.
News ESMO26: Evidence for GSK's mo-rez builds in ovarian cancer New data from GSK's BEHOLD-1 study of B7-H4-targeted ADC mo-rez reinforce earlier results in platinum-resistant ovarian cancer.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.